Hydroxychloroquine corrects mitochondrial recycling dysfunction in natural killer cells from patients with systemic lupus erythematosus

Natalia Fluder[1], Morgane Humbel[2], Emeline Recazens[3], Alexis A. Jourdain[3], Camillo Ribi[1], George C. Tsokos[2], Denis Comte[4]

[1] Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.

[2] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.

[3] Department of Immunobiology, University of Lausanne, 1066 Epalinges, Switzerland.

[4] Department of Medicine, Division of Internal Medicine, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.

Corresponding author:

Dr. Denis Comte

Department of Medicine

Division of Internal Medicine

46, Rue du Bugnon

1011 Lausanne

Switzerland

T +41 21 314 81 31

denis.comte@chuv.ch

ABSTRACT

Objectives Natural Killer (NK) cell dysfunction contributes to systemic lupus erythematosus (SLE) pathogenesis, but the underlying mechanisms remain poorly understood. This study investigates immunometabolic alterations in NK cells from SLE patients and explores therapeutic strategies for their restoration.

Methods We characterized mitochondrial structure and function in NK cells from the peripheral blood of SLE patients and healthy controls using flow cytometry, electron microscopy, and proteomics. Key mitophagy-related gene expressions were quantified using qPCR. The ability of hydroxychloroquine (HCQ) to restore mitochondrial recycling and NK cell function were assessed *in vitro.*

Results SLE NK cells displayed accumulated enlarged, hyperpolarized mitochondria with cristae disorganization, and reduced mitophagy. Impaired lysosomal acidification and mtDNA extrusion into the cytosol were also observed. Treatment with HCQ restored mitochondrial recycling, and NK cell effector functions, including cytokine production and cytotoxicity by acidifying lysosomes.

Conclusions This study identifies mitochondrial recycling dysfunction as a driver of NK cell abnormalities in SLE patients. HCQ can correct these abnormalities by acidifying the lysosomes and highlights the potential of HCQ to restore NK cell functionality. These findings provide new insights into the immunometabolic mechanisms underlying SLE and suggest avenues for targeted therapeutic interventions.

WHAT IS KNOWN ON THE TOPIC

➢ SLE is a complex inflammatory disease characterized by the development of autoreactive cells and a breakdown of self-tolerance (1, 2).

➢ Natural Killer (NK) cells, pivotal players in the innate immune system, exhibit reduced numbers, diminished cytotoxicity, and impaired cytokine production in SLE patients (3-5).

➢ Peripheral $CD56^{dim}CD57^{+}$ NK cells from SLE patients exhibit increased endogenous apoptosis and higher levels of mitochondrial (mt)ROS, contributing to their altered function (6).

WHAT THE STUDY ADDS

➢ This study reveals a full spectrum of immunometabolic alterations in Natural Killer (NK) cells from SLE patients, including hyperpolarized mitochondria accumulation, cristae disorganization and impaired mitophagy. These results identify mitochondrial recycling dysfunction as a central factor in NK cell abnormalities in SLE.

➢ It demonstrates for the first time that hydroxychloroquine (HCQ), a standard treatment for SLE, effectively restores mitochondrial recycling in NK cells by modulating lysosomal acidification, reducing cytosolic leakage of mtDNA and enhancing the expression of mitophagy-related genes.

➢ These results highlight a new mechanism by which HCQ attenuates immune dysregulation, making it a potential targeted approach for treating the specific dysfunction of NK cells in SLE.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

➢ Understanding how mitochondrial recycling dysfunction impacts SLE pathogenesis can pave the way for the development of targeted therapies and improved disease management for SLE patients.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a multi-systemic inflammatory autoimmune disease of unknown etiology, which mainly affects women of childbearing age. SLE is characterized by a breakdown in immune tolerance resulting in the production of autoantibodies, immune complexes and autoreactive cells, which subsequently lead to organ damage (7). Although the contribution of different peripheral blood mononuclear cells (CD4+ T, CD8+ T cells and B cells) to the pathogenesis SLE has been widely examined, the precise mechanisms responsible underlying tolerance breakdown remain elusive (8, 9).

Natural Killer (NK) cells represent a group of innate immune cells that play a pivotal role in the interface between the innate and adaptive immune system (10). These cytotoxic lymphocytes play an essential role in immune surveillance, including recognition of healthy cells and defense against viral infections and transformed cells. However, their contribution to autoimmune diseases like SLE remains poorly understood (10). Numerous studies have highlighted NK cell dysfunction in SLE, including reduced numbers in peripheral blood, impaired cytokine production (TNFα, IFNy), reduced cytotoxicity, and defective antibody-dependent cellular cytotoxicity (ADCC) (4, 5, 11, 12). These dysregulations may contribute to SLE disease progression by disrupting NK cell interaction with plasma cells, contributing to the persistence of autoantibody-producing cells (3, 13). Additionally, compromised NK cell function may affect therapeutic responses, as monoclonal antibody treatments like rituximab rely on ADCC, a mechanism mediated by functional NK cells (14, 15).

Emerging evidence implicates mitochondrial dysfunction as a central driver of immune cell dysregulation in SLE. In SLE, T cells have been shown to exhibit mitochondrial dysfunction, characterized by increased mitochondrial mass (megamitochondria), mitochondrial hyperpolarization, and ATP depletion. These abnormalities contribute to aberrant activation and necrotic debris deposition, ultimately driving autoantibody production - a hallmark of SLE pathogenesis (16, 17). Moreover, mitophagy, a critical mitochondrial quality control process, is impaired in T cells from SLE patients and lupus-prone mice, with RAB4A overexpression disrupting lysosomal degradation (16-20) Given the dependence of NK cell function on metabolic fitness, we hypothesized that similar mitochondrial abnormalities might contribute to NK cell dysfunction in SLE(16, 21)

In the present study, we performed a comprehensive analysis of the mitochondrial homeostasis in NK cells from SLE patients, compared to matched healthy controls. Our aim was to elucidate how immunometabolic abnormalities disrupt NK cell function and contribute to SLE pathogenesis. Furthermore, we explored potential strategies to restore mitochondrial and NK cell function, offering new insights into targeted approaches for managing SLE.

METHODS

Cohort

SLE patients (n= 104) were diagnosed according to the 1997 revised American College of Rheumatology (ACR) classification criteria and/or the Systemic Lupus International Collaborating Clinics (SLICC) criteria(22, 23). Patients were recruited from the Division of Immunology and Allergy at Centre Hospitalier Universitaire Vaudois (CHUV). All participants, including heathy controls, were enrolled in the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)(24). Informed written consent was obtained from all participants prior to inclusion and the study was approved by the Institutional Review Board (SwissEthics 2017-01434), in compliance with the Declaration of Helsinki. Characteristics of the SLE patients included in this study are provided in Table 1.

PBMC isolation & **cell culture** Peripheral blood mononuclear cells (PBMCs) were enriched by density gradient centrifugation FICOLL 400 (Merck, Switzerland). The PBMCs were cryopreserved in liquid nitrogen for downstream analyses.

Cells were cultured in RPMI (Gibco; Life Technologies) containing 10% heat inactivated fetal bovine serum (FBS; Institut de Biotechnologies Jacques Boy), 100 IU/ml penicillin and 100 µg/ml streptomycin (Bio Concept), referred to as complete RPMI (cRPMI).

Flow cytometry

PBMCs from SLE patients and healthy controls were thawed in PRMI containing 20% FBS, centrifuged, resuspended in cRPMI, and pelleted. Cells were stained with Live/Dead-APC-H7 or PB (Invitrogen) and cell surface antibodies: CD3-BUV737or APC-H7, CD56-BUV395, in parallel to different fluorescent probes specific to mitochondrial fitness, superoxides and lysosomal acidification.

NK cell mitochondrial fitness PBMCs were incubated for 20min at 37°C with the cell-permeable fluorescent probes MitoTracker Green and MitotTacker Red (Invitrogen). MitoTracker Green measured mitochondrial mass, while MitoTracker Red assessed the mitochondrial membrane potential ($\Delta\Psi_m$). Cells stained with MitoTracker Red were fixed BD CellFIX™ before analysis on LSR Fortessa™ (BD Bioscience)

NK cell mitochondrial superoxides PBMCs were incubated for 15 min at 37°C, in presence of the MitoSOX fluorescent probe (Invitrogen). PBMCs stained with MitoSOX were analysed on LSR Fortessa™ (BD Bioscience).

NK cell lysosomal acidification PBMCs were incubated for 30-45 min at 37°C, with LysoTracker (Invitrogen) and LysoSensor (Invitrogen) probes to assess lysosomal number and pH, respectively. PBMCs stained with LysoTracker and LysoSensor were analysed on LSR Fortessa™ (BD Bioscience).

NK cell cytokine production and degranulation PBMCs were stimulated with or without cytokines (IL-2 and IL-12, 50ng/ml and 20ng/ml respectively) for 6 hours at 37°C. BD GolgiPlug™, BD GolgiStop™ and CD107a-PE were added 4h before readout. After incubation, cells were stained with Live/Dead-APC-H7 and cell surface antibodies: CD3-BUV737, CD4-PB, CD8-BV605, CD19-FITC, CD56-BUV395. After permeabilization with BD Cytofix/Cytoperm™ kit, cells were stained with IFNγ-AF700, TNFα-APC. before analysis on LSR Fortessa™ (BD Bioscience).

NK cell isolation

Natural killer (NK) cells were enriched from SLE and healthy PBMCs using the human NK isolation kit (Miltenyi) with negative labeling. The labeled PBMCs were processed through the AutoMACS® ProSeparator (Miltenyi Biotec).

NK cell cytosol/mitochondria fragmentation

NK cells were isolated from SLE and healthy controls PBMCs. Cytosolic, mitochondrial, and whole-cell extract fractions were separated using the cytosol/mitochondria fragmentation kit (Abcam) according to the manufacturer's instructions. Briefly, isolated NK cells were washed in PBS and pelleted by centrifugation at 600g for 5 min. The cell pellet was resuspended in the cytosol extraction buffer and incubated on ice for 10 min, followed by homogenization with a syringe. The homogenate was centrifuged at 1000g for 10 min, and the supernatant, containing the cytosolic fraction, was collected.

This supernatant was further centrifuged at 10000g for 30 min. Both supernatant and cell pellet resulting from the last centrifugation were saved as cytosolic fraction and mitochondria, respectively. The mitochondria were resuspended in the mitochondrial extraction buffer and saved as the mitochondrial fraction.

The whole cells extract was obtained by centrifugating NK cells at the initial step, without fractionation. DNA was extracted from all the obtained fractions (cytosolic, mitochondrial, whole cell) using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions.

Quantification of mitochondrial DNA (mtDNA) content

The mtDNA content in different NK subcellular fractions was quantified using qPCR targeting NADH deshydrogenase 2 (ND2) and D-Loop (displacement loop). Amplifications were performed using PowerTrack SYBR Green and TaqMan Universal PCR Master Mixes (Life Technologies Europe BV). Data were acquired with the QuantStudio™ 6 Flex Real-Time PCR System (ThermoFisher Scientific). Quantification of the mtDNA content in the cytosol of healthy and SLE NK cells was assessed following the basic protocol 2 as previously described (21). Results were normalized to Alu repeat sequence. Primers for qPCR were ordered from Microsynth and are detailed in supplementary materials.

Mitophagy genes expression

RNA was extracted from NK cells of SLE and healthy controls using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's instructions. Complementary DNA was synthesized, and real-time qPCR was performed with SuperScript™ III Platinum™ SYBR™ Green One-Step qRT-PCR Kit (Life Technologies). The expression of mitophagy-related genes including light chain 3B (LC3B), Lysosome-associated membrane protein 2 (LAMP2), PTEN Induced Kinase 1 (PINK1), Parkinson disease 2 (PARK2), class III phosphatidylinositol 3-kinase (PIKC3C), GABA Type A Receptor Associated Protein Like 1 (GABARAPL1), Unc-51-like kinase 1 (ULK1), Beclin 1 (BECN1) genes was assessed using the QuantStudio™ 6 Flex Real-Time PCR System (ThermoFisher Scientific). Results were normalized to the expression β-actin. Primers were ordered from Microsynth (supplementary data).

Transmission electron microscopy (TEM)

TEM was performed on NK cells isolated from the peripheral blood of SLE (n=5) patients and healthy controls (n=5). Detailed procedures are provided in the online supplemental materials.

Proteomics analyses

Liquid Chromatography-Mass Spectrometry (LC-MS/MS) analyses were performed on NK cells isolated from the peripheral blood of SLE patients (n=4) and healthy controls (n=4). Detailed procedures are provided in the online supplemental materials. All raw MS data, along with processed raw output tables, are publicly available via the ProteomeXchange data repository (www.proteomexchange.org) with the accession code PXD059825

Statistics

Statistical analyses were performed using GraphPad Prism (version 10). Details of the statistical tests and sample sizes for each experiment are provided in the corresponding figure legends.

For comparisons between two groups with non-normal distributions, the Mann-Whitney U test was used (normality assessed via the Shapiro-Wilk test). For multiple group comparisons with non-normal distributions, the Kruskal-Wallis test was applied, with p-values adjusted using Dunn's method. For multiple group comparisons with normal distributions, one-way ANOVA was used, with p-values adjusted using the Sidak method. Two-way ANOVA was used for comparisons involving two independent variables, with p-values adjusted using Sidak's or Tukey's methods as appropriate. A p-value <0.05 was considered statistically significant.

RESULTS

NK cells from SLE patients accumulate enlarged dysfunctional mitochondria.

The numbers of NK cells are reduced in patients with SLE and exhibit impaired degranulation and altered cytokine production. Given that mitochondrial dysfunction has been demonstrated in SLE CD8+ T cells, we sought to investigate whether similar abnormalities contribute to NK cell dysfunction by assessing their mitochondrial fitness (3, 6, 17, 25, 26). Mitochondrial function was evaluated using flow cytometry to measure mitochondrial mass, membrane potential, and activity. Our findings showed

a significant increase in mitochondrial mass (figure 1A, D) and hyperpolarization of the mitochondrial membrane (figure 1B), accompanied by a reduction in mitochondrial activity (figure 1C). Although increased mitochondrial mass was observed in other PBMC populations such as B and T cells, this alteration was most pronounced in NK cells from SLE patients compared to healthy controls (supplementary figure 1A).

To determine whether these functional abnormalities correspond to structural changes, we performed transmission electron microscopy (TEM) analysis on NK cells from SLE patients and healthy controls. TEM revealed that the area occupied by mitochondria was significantly larger in SLE NK cells compared to controls (figure 1E, F). By analyzing 50 TEM images per group, we quantified both mitochondrial area and number. TEM confirmed an increase in mitochondrial size in SLE NK cells, while qPCR analysis showed that the mitochondrial genome remained the same, as indicated by the ratio of mitochondrial to genomic DNA (figure 1G). These findings demonstrate that NK cells from SLE patients accumulate enlarged but dysfunctional mitochondria, indicating impaired mitochondrial clearance.

Defective Lysosomal Acidification Drives Mitochondrial Dysfunction in SLE NK Cells.

To further investigate the mechanisms underlying mitochondrial dysfunction in SLE NK cells, we performed a quantitative proteomic analysis focusing our data analysis on proteins associated with mitochondrial homeostasis. Proteomic profiling revealed increased expression of proteins related to mitochondrial fragmentation (OPA3), suppression of mitophagy (SLC39A7), ER protein retention (KDELR2), negative regulation of NK cell function (NFATC4), mRNA degradation (CNOT10), activation of the NLRP3 inflammasome (APOC3) and metabolites flow through a mitochondrial channel (VDAC1). Conversely, we observed a reduction in proteins key for mitochondrial function (MT-ATP6), energy homeostasis in ER (G6PC3), mitochondrial clearance (MARCHF5) and cellular redox balance, involved in the switching-on of mitophagy (MSRB2) (figure 2A, B).

Gene ontology (GO) enrichment analysis also revealed an upregulation of pathways involved in response to DNA damage and DNA metabolic process, along with a downregulation of genes associated with vesicle acidification and trafficking (figure 2C). These findings pointed to potential disruptions in lysosomal function, a critical component of vesicle trafficking. To investigate this, we

assessed lysosomal trafficking and acidification in SLE NK cells using flow cytometry. Fluorescent probes specific for lysosomal number and pH revealed that, while the lysosomal number in SLE NK cells was comparable to healthy controls (figure 2D), the lysosomal pH was significantly more alkaline in SLE NK cells (figure 2E). These results suggest that impaired lysosomal acidification may contribute to the functional deficits observed in SLE NK cells, providing new insights into disease pathology.

To explore whether lysosomal acidification defects could drive mitochondrial abnormalities in SLE NK cells, we treated healthy NK cells with bafilomycin A1, a V-ATPase inhibitor. Bafilomycin A1 treatment resulted in increased mitochondrial mass (figure 2F) and inhibited lysosomal acidification, reproducing the mitochondrial phenotype observed in SLE NK cells (figure 2G). Moreover, bafilomycin A1 (100nM) treatment led to the extrusion of mitochondrial DNA (mtDNA) into the cytosol of healthy NK cells after overnight incubation (figure 2H). These findings establish a critical link between defective lysosomal acidification and mitochondrial dysfunction in SLE NK cells. Impaired lysosomal function likely contributes to the accumulation of enlarged, dysfunctional mitochondria and the cytosolic release of mtDNA, further exacerbating immune dysregulation in SLE.

NK cells from SLE patients harbor functionally and structurally damaged mitochondria with an altered mitochondrial recycling.

Mitochondrial function is essential in maintaining a redox homeostasis where mitochondrial reactive oxygen species (mROS) play a central role in immune regulation. An unbalanced mROS production, leads to apoptosis, insufficient cellular debris clearance, oxidative damage, diminished ATP production, and immune dysregulation characterized by skewing pro inflammatory signaling in Th17 cells (6, 27).

In our study, mitochondria from SLE NK cells displayed increased levels of superoxide (figure 3A), predisposing them to mitochondrial damage, impaired debris clearance, and increased susceptibility to apoptosis. Electron microscopy showed alterations in the ultrastructure of the mitochondria of SLE NK cells, including mitochondrial cristae disorganization (figure 3B). Given that mitochondrial cristae integrity is crucial for maintaining mtDNA compartmentalization and preventing inflammation, we hypothesized that these structural alterations could facilitate the release of mtDNA into the cytosol. To test this, we performed qPCR analysis to quantify the relative abundance of mtDNA in the cytosol and

found significantly higher levels in SLE NK cells compared to healthy controls (figure 3C, D), indicating increased mitochondrial membrane permeability and impaired compartmentalization of mtDNA.

In parallel, proteomic analysis of SLE NK cells indicated significant disruptions in mitochondrial homeostasis and clearance mechanism. To further investigate these findings, we measured the expression of key mitophagy-related genes in NK cells from SLE patients and healthy controls using RT-qPCR. Since lysosomal trafficking inhibition is known to induce the accumulation of enlarged mitochondria in healthy NK cells, we examined multiple stages of the autophagy pathway to evaluate the mitophagic flux in SLE NK cells. Our results demonstrated a significant reduction in the expression of genes essential for the PINK1-Parkin–dependent macroautophagy pathway, including, LAMP2, PINK1, PARK2, PIKC3C, GABARAPL2 and BECL1 genes (figure 3E).

Together, these findings reveal that SLE NK cells harbor mitochondria with both functional and structural damage, driven in part by impaired mitophagy. These defects likely contribute to the accumulation of dysfunctional mitochondria, mtDNA release, and immune dysregulation, highlighting a critical role for mitochondrial and autophagic pathways in SLE NK cells dysfunction.

Hydroxychloroquine restores NK cell function and mtDNA compartmentalization in SLE patients.

We and others have previously demonstrated that NK cell function is severely impaired in SLE, characterized by defective production of IFNγ and TNFα and impaired degranulation (as illustrated by decreased CD107a expression) (3, 4, 28). Building on these findings, our work here shows that SLE NK cells also exhibit mitochondrial dysfunction, impaired mitophagy, and diminished effector functions. To explore whether HCQ, a widely used therapeutic in SLE, could restore these cellular processes, we evaluated its effects on NK cell activation, mitochondrial recycling, and mitophagy-related gene expression (supplementary figure 2).

In vitro treatment of stimulated SLE NK cells with HCQ reversed their reduced cytotoxicity and cytokine production, restoring these functions to levels observed in healthy controls (figure 4A, B, C) To investigate whether HCQ could also address mitochondrial dysfunction, we examined its effects on lysosomal acidification. Our data demonstrated that HCQ effectively acidifies lysosomes in SLE NK

cells (figure 4D, E). Moreover, we investigated the impact of HCQ on mtDNA release into the cytosol, a hallmark of mitochondrial dysfunction in SLE NK cells. Stimulation with HCQ significantly reduced the relative levels of cytosolic mtDNA in NK cells from healthy controls, compared to untreated cells (figure 4F, G).

Hydroxychloroquine restores the mitochondrial recycling in NK cells from SLE patients.

Finally, we examined the effect of HCQ on the expression of key mitophagy-related genes. Overnight incubation with HCQ restored the expression of LC3B, LAMP2, PINK1, PARK2, PIK3C3, GABARAPL2, ULK1 and BECL1 in SLE NK cells to levels comparable to those of healthy controls (figure 5).

Together, these findings demonstrate that HCQ not only restores NK cell effector functions but also addresses mitochondrial and autophagic dysregulation in SLE, highlighting its potential therapeutic benefits in managing NK cell dysfunction.

DISCUSSION

NK cells are essential components of the immune system, playing key roles in antiviral defense, tumor surveillance, and immune regulation through cytotoxic activity and cytokine production (5). In SLE, NK cells exhibit profound dysfunction, including reduced cytotoxicity, impaired degranulation, and diminished cytokine production (e.g., IFNγ and TNFα) (6–8). These defects have significant implications for SLE pathogenesis. First, the inability to eliminate virally infected and transformed cells increases susceptibility to infections and malignancies in SLE patients.(29) Second, the failure to clear autoreactive cells, such as antibody-producing plasma cells, CD4+ T cells, and dendritic cells, exacerbates autoantibody production and contributes to inflammation, immune complex deposition, and tissue damage (30-32). Third, NK cell dysfunction compromises antibody-dependent cellular cytotoxicity (ADCC), undermining the efficacy of monoclonal antibody therapies such as rituximab, particularly in severe cases like lupus nephritis (14, 15).

To elucidate the mechanisms underlying NK cell dysfunction in SLE, we focused on their immunometabolic regulation, with particular attention to mitochondrial fitness and recycling. Our findings revealed significant mitochondrial abnormalities in SLE NK cells, including increased mitochondrial mass, hyperpolarized membranes, and reduced activity, indicative of severe mitochondrial dysfunction. Additionally, defects in mitophagy, a critical mitochondrial quality control pathway, were observed, with SLE NK cells exhibiting reduced expression of genes involved in PINK1-Parkin–dependent macroautophagy pathway (LAMP2, PINK1, PARK2, PIKC3C, GABARAPL2, BECL1) and impaired lysosomal acidification.

Downregulation of these genes impairs different stages of the mitophagy process, from the recognition and marking of damaged mitochondria (PINK1, PARK2), to autophagosome formation (GABARAPL1, PIK3C3, BECN1), and the fusion with lysosomes (LAMP2). Dampened GABARAPL1, PIK3C3 and BECN1 expression, hampers the initiation of autophagy through disrupted autophagosome formation and cargo selection. Reduced PINK1 and PARK2 expression, prevents the identification of dysfunctional mitochondria, resulting in their prolonged presence within cells. Insufficient LAMP2 impairs lysosomal degradation of autophagosomes. These abnormalities result in the accumulation of dysfunctional mitochondria leading to oxidative stress and the extrusion of mitochondrial DNA (mtDNA) into the cytosol, a key driver of inflammation through activation of cGAS and type I interferon responses, contributing to the amplification of autoimmune mechanisms. Together, these findings suggest that mitochondrial dysfunction and impaired mitophagy are central to NK cell abnormalities and broader immune dysregulation in SLE.

HCQ, a standard therapy for SLE, is widely used to reduce disease activity, prevent flares, and decrease corticosteroid dependency, with additional benefits such as thrombotic risk reduction and improved pregnancy outcomes (21, 22). At a molecular level, HCQ accumulates in lysosomes, modulating pH and affecting key processes like autophagy, antigen presentation, and cytokine production. While high doses (5–50 µM) can impair lysosomal function and induce toxicity, our study demonstrated that low, clinically relevant, doses (0.1–1 µM) effectively restore NK cell function without cytotoxic effects. Specifically, HCQ reversed mitochondrial dysfunction, improved lysosomal acidification, and restored the expression of mitophagy-related genes. Additionally, HCQ reduced the release of mtDNA into the cytosol, mitigating a major source of immune dysregulation in SLE. These

findings underscore HCQ's ability to target the immunometabolic pathways underlying NK cell dysfunction.

Several limitations should be acknowledged. The sample size was relatively small, and variability in patient treatment regimens may have influenced the findings. Additionally, the cross-sectional design limits the ability to assess longitudinal changes or causal relationships. Future studies should include larger, more homogenous cohorts and longitudinal analyses to validate these results. Furthermore, the *in vitro* experimental conditions may not fully replicate the complexity of the *in vivo* environment, necessitating further preclinical and clinical investigations.

In conclusion, our work highlights mitochondrial dysfunction and impaired mitophagy as central drivers of NK cell abnormalities in SLE. Moreover, HCQ's ability to restore mitochondrial and lysosomal function underscores its therapeutic potential not only as an immunomodulator but also as a targeted agent addressing NK cell immunometabolism. These findings provide critical insights into the molecular basis of NK cell dysfunction in SLE and suggest new avenues for targeted therapies to restore NK cell function and improve clinical outcomes in SLE.

CONCLUSION

This study highlights mitochondrial dysfunction and impaired mitophagy as central factors in Natural Killer (NK) cell abnormalities in systemic lupus erythematosus (SLE), leading to immune dysregulation and contributing to disease pathogenesis. By demonstrating that HCQ restores m mitochondrial recycling, lysosomal acidification, and dysregulation NK cell effector functions, our results reveal an essential mechanism by which NK cell functionality can reactivated. Crucially, this study suggests that targeting NK cell dysfunction improves not only their cytotoxic and immunoregulatory roles, but also the therapeutic efficacy of existing therapies that rely on NK cell-mediated mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC). This knowledge makes NK cell activation an essential strategy for optimising drug response and advancing personalised therapeutic approaches in SLE. This paradigm shift highlights the potential of therapies such as HCQ to act as immunometabolic modulators, bridging the gap between molecular dysfunction and clinical outcomes, and paving the way for improved disease management in SLE.

Data availability The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author Contributions: NF, DC: study design and data analysis. NF, MH, ER: conducting experiments, data acquisition and analysis. NF, CR, DC: recruitment of SLE patients and healthy controls. NF, DC: writing and editing of manuscript. MH, GT, ER, AJ, CR: critical reading of the manuscript. All authors contributed to the article and approved the submitted version.

Funding This work was funded by a grant from the Swiss National Science Foundation Ambizione PZ00P3_173950 (DC), a grant from the Novartis Foundation 173950 (DC), a grant from the National Science Foundation 310030_200796 (AJ) and PHS NIH R01AI148161 (GCT).

Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments We thank the personnel of the vaccine and immunotherapy center for the isolation of SLE PBMC cells, study nurse Emmanuelle Paccou and the physicians of the division of immunology and allergy, for their help with patient recruitment, and the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) for their support. We also thank the staff of the UNIL electron microscopy and proteomic facilities for performing NK cell imaging and protein expression analysis for us.

References

1.   Tsokos GC. The immunology of systemic lupus erythematosus. Nat Immunol. 2024;25(8):1332-43.
2.   Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends Mol Med. 2017;23(7):615-35.
3.   Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, et al. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. Front Immunol. 2021;12:645478.
4.   Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 2009;60(6):1753-63.
5.   Spada R, Rojas JM, Barber DF. Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. J Leukoc Biol. 2015;98(4):479-87.

6.   Lu Z, Tian Y, Bai Z, Liu J, Zhang Y, Qi J, et al. Increased oxidative stress contributes to impaired peripheral CD56(dim)CD57(+) NK cells from patients with systemic lupus erythematosus. Arthritis Res Ther. 2022;24(1):48.

7.   Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-21.

8.   Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol. 2010;42(4):543-50.

9.   Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in Systemic Lupus Erythematosus. Curr Opin Immunol. 2016;43:32-8.

10.   Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 2008;15(2):226-33.

11.   Tsokos GC, Rook AH, Djeu JY, Balow JE. Natural killer cells and interferon responses in patients with systemic lupus erythematosus. Clin Exp Immunol. 1982;50(2):239-45.

12.   Rook AH, Tsokos GC, Quinnan GV, Jr., Balow JE, Ramsey KM, Stocks N, et al. Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus. Clin Immunol Immunopathol. 1982;24(2):179-85.

13.   Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med. 1993;177(1):155-64.

14.   Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-33.

15.   Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-26.

16.   Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, et al. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis. 2014;73(10):1888-97.

17.   Chen PM, Katsuyama E, Satyam A, Li H, Rubio J, Jung S, et al. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci Adv. 2022;8(24):eabo4271.

18.   Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, et al. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol. 2009;182(4):2063-73.

19.   Caza TN, Talaber G, Perl A. Metabolic regulation of organelle homeostasis in lupus T cells. Clinical Immunology. 2012;144(3):200-13.

20.   Zhao L, Hu X, Xiao F, Zhang X, Zhao L, Wang M. Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus. Front Immunol. 2022;13:929520.

21.   Bryant JD, Lei Y, VanPortfliet JJ, Winters AD, West AP. Assessing Mitochondrial DNA Release into the Cytosol and Subsequent Activation of Innate Immune-related Pathways in Mammalian Cells. Curr Protoc. 2022;2(2):e372.

22.   Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7.

23.   Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86.

24.   Ribi C, Trendelenburg M, Gayet-Ageron A, Cohen C, Dayer E, Eisenberger U, et al. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) – cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss Medical Weekly. 2014;144(3132):w13990.

25.   Quintero-González DC, Muñoz-Urbano M, Vásquez G. Mitochondria as a key player in systemic lupus erythematosus. Autoimmunity. 2022;55(8):497-505.

26.   Morel L. Immunometabolism in systemic lupus erythematosus. Nature Reviews Rheumatology. 2017;13(5):280-90.

27.   Yang J, Yang X, Zou H, Li M. Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus. Oxid Med Cell Longev. 2016;2016:2526174.

28.   Schleinitz N, Vély F, Harlé J-R, Vivier E. Natural killer cells in human autoimmune diseases. Immunology. 2010;131(4):451-8.

29.   Mace EM, Orange JS. Emerging insights into human health and NK cell biology from the study of NK cell deficiencies. Immunol Rev. 2019;287(1):202-25.

30.   Schuster IS, Wikstrom ME, Brizard G, Coudert JD, Estcourt MJ, Manzur M, et al. TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. Immunity. 2014;41(4):646-56.

31.   Cruz-González DJ, Gómez-Martin D, Layseca-Espinosa E, Baranda L, Abud-Mendoza C, Alcocer-Varela J, et al. Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus. Clin Exp Immunol. 2018;191(3):288-300.

32.   Yang Y, Day J, Souza-Fonseca Guimaraes F, Wicks IP, Louis C. Natural killer cells in inflammatory autoimmune diseases. Clin Transl Immunology. 2021;10(2):e1250.

Table 1:

CHARACTERISTICS		Value (N)
Age, years		
	Median (SD)	42 (12.9)
	Range	20-80
Sex		
	Female (%)	92 (88.5)
	Male (%)	12 (11.5)
SLE disease activity		
	Inactive (SLEDAI : 0-3) (%)	48 (44.5)
	Moderate (SLEDAI: 4-10) (%)	29 (29.3)
	Active (SLEDAI>10) (%)	23 (23.2)
Treatment		
	Naïve (%)	8 (7.7)
	Prednisone (%)	57 (54.8)
	Hydroxychloroquine (%)	74 (71.5)
	Hydroxychloroquine alone (%)	27 (26)
	Other immunomodulatory drugs (%)*	44 (42.3)

* Azatioprine, Belimumab, Cyclosporin, Etanercept, Methotrexate, Mycophenolate mofetil Rituximab, Tacrolimus.

Figure legends

Figure 1: NK cells from SLE patients accumulate enlarged dysfunctional mitochondria. (A, D) Mitochondrial mass, (B) membrane potential, and (C) activity in NK cells from healthy controls (HC; n=16) and SLE patients (n=16), assessed at baseline by flow cytometry using the MFI of MitoTracker Green, MitoTracker Red, and their ratio, respectively. Measurements were taken at baseline, after 1 hour (A–C), or after overnight resting (D). Each symbol represents an individual donor. *p<0.05, by Wilcoxon test. (E) NK cells were isolated from the peripheral blood of HC (n=5) and SLE patients (n=5) and processed for transmission electron microscopy (TEM). Representative TEM images of NK cells from HC and SLE patients at x500 magnification. Red arrows depict examples of the abnormal mitochondria. (F) Mitochondrial area per NK cell was measured on 10 different TEM images per individual from HC (n=5) and SLE patients (n=5) using the grid overlay technique. Each symbol represents a single NK cell. *p<0.05, by Wilcoxon test. (G) NK cells isolated from HC (n=12) and SLE patients (n=11) were analyzed by qPCR on whole cell extracts at baseline. Relative abundance of total mitochondrial DNA (mtDNA) was quantified using the expression of the ND2 gene and normalized to their mean within HC samples. Each symbol represents an individual donor. A Log2 fold change (FC) >0.5 or <-0.5 was considered significant, by Wilcoxon test. HC, healthy controls; SLE, systemic lupus erythematosus; MFI, mean fluorescence intensity; mitochondrial activity, ratio of mitochondrial membrane potential to mass; TEM, transmission electron microscopy; ND2, NADH dehydrogenase 2 gene; FC, fold change.

Figure 2: NK cells from SLE patients fail to correctly acidify their lysosomes and maintain mitochondrial homeostasis. (A) LC-MS–based proteomics was performed on NK cells isolated from the peripheral blood of healthy controls (HC; n=4) and SLE patients (n=4). The volcano plot shows the protein expression levels in NK cells from SLE patients versus HC at baseline. Differentially expressed proteins (Log2 fold change [FC] >0.5 or <-0.5) are highlighted in red (upregulated) and blue (downregulated), based on four experiments. (B) Gene ontology enrichment analysis of differentially expressed proteins in NK cells from SLE patients compared to HC at baseline. (C) Selected significantly upregulated (red) and downregulated (blue) proteins in NK cells from SLE patients compared to HC (p<0.05 and Log2 FC >0.5 or <-0.5, based on four experiments). (D, E) Lysosomal

number (D) and lysosomal pH (E) in NK cells from HC and SLE patients were assessed by flow cytometry at baseline using the mean fluorescence intensity (MFI) of fluorescent probes (LysoTracker for lysosomal number and LysoSensor for lysosomal pH, respectively). Each symbol represents an individual donor. *p<0.05, by Wilcoxon test. (F, G) NK cells from HC and SLE patients were stimulated overnight with or without rotenone, bafilomycin (100 nM), or subjected to starvation. Mitochondrial mass (F) and lysosomal number (G) in total NK cells were assessed by flow cytometry using the MFI of MitoTracker Green and LysoTracker, respectively. Each symbol represents an individual donor. *p<0.05, by Friedman and Wilcoxon test. (H) NK cells from HC (n=11) and SLE patients (n=11) were stimulated overnight with or without bafilomycin (100 nM) and fractionated using differential ultracentrifugation. qPCR analysis was performed on the whole-cell extract, cytosolic fraction, and mitochondrial fraction. The relative abundance of cytosolic mtDNA in NK cells was assessed using the expression of the ND2 and D-Loop genes. Each symbol represents an individual donor. Data were normalized to HC samples. A Log2 FC >0.5 or <-0.5 was considered significant. Rotenone was used as a positive control for mitochondrial mass, bafilomycin as a negative control for lysosomal trafficking, and starvation as a positive control for lysosomal trafficking. LC-MS, liquid chromatography-mass spectrometry; mtDNA, mitochondrial DNA; ND2, NADH dehydrogenase 2 gene; D-Loop, mitochondrial DNA displacement loop structure gene; MFI, mean fluorescence intensity.

Figure 3: NK cells from SLE patients harbor damaged mitochondria with disrupted ultrastructure and impaired mitophagy. (A) Mitochondrial superoxide levels in NK cells from healthy controls (HC) and SLE patients were assessed by flow cytometry, based on the frequency of the MitoSOX+/MitoTracker Green+ population. Each symbol represents an individual donor. *p<0.05, by paired t-test. (B) Left panel: representative TEM image of an NK cell from an SLE patient at x5000 magnification, highlighting mitochondrial damage. Right panel: higher magnification TEM image (x15000) showing mitochondrial ultrastructure abnormalities in an NK cell from an SLE patient. (C, D) NK cells isolated from the peripheral blood of HC (n=10) and SLE patients (n=10) were fractionated using differential ultracentrifugation. qPCR analysis was performed on the whole-cell extract, cytosolic fraction, and mitochondrial fraction at baseline. The relative abundance of cytosolic mtDNA was assessed using the expression of the ND2 (C) and D-Loop (D) genes and normalized to their mean expression within HC samples. Each symbol represents an individual donor. A Log2 fold change (FC) >0.5 or <-0.5 was considered significant, by Mann-Whitney test. (E) NK cells from HC (n=12) and SLE patients (n=12)

were analyzed by RT-qPCR at baseline to determine the relative expression of mitophagy-related genes (LC3B, LAMP2, PINK1, PIKC3C, GABARAPL2, ULK1, BECL1, and PARK2). Specific genes expression was determined by normalization to their mean expression within HC samples. Each symbol represents an individual donor. A Log2 FC >0.5 or <-0.5 was considered significant, by Mann-Whitney test. MitoSOX, mitochondrial superoxides; MTK, MitoTracker; mtDNA, mitochondrial DNA; TEM, transmission electron microscopy; ND2, NADH dehydrogenase 2 gene; D-Loop, mitochondrial DNA displacement loop structure gene; LC3B, light chain 3B; LAMP2, Lysosome-associated membrane protein 2; PINK1, PTEN Induced Kinase 1; PARK2, Parkinson disease 2; PIKC3C, class III phosphatidylinositol 3-kinase; GABARAPL1, GABA Type A Receptor Associated Protein Like 1; ULK1, Unc-51-like kinase 1; BECN1, Beclin 1;

Figure 4: Hydroxychloroquine restores the cell function and mtDNA compartmentalization in NK cells from SLE patients. (A) Degranulation and (B, C) cytokine production (IFNγ, TNFα) in NK cells from healthy controls (HC) and SLE patients were assessed by flow cytometry, based on the frequency of CD107α + (A), IFNγ+ (B), and TNFα+ (C) cells. Each symbol represents an individual donor. *p<0.05, **p<0.01, ***p<0.001, by Kruskal-Wallis test. (D, E) Lysosomal number (D) and lysosomal pH (E) in NK cells from HC and SLE patients were assessed by flow cytometry at baseline using the MFI of fluorescent probes (LysoTracker for lysosomal number and LysoSensor for lysosomal pH). Each symbol represents an individual donor. *p<0.05, **p<0.01, ***p<0.001, by Kruskal-Wallis test. (F,G) NK cells isolated from the peripheral blood of HC (n=10) and SLE patients (n=10) were fractionated using differential ultracentrifugation following overnight stimulation with or without hydroxychloroquine (HCQ,1 μM). qPCR analysis was performed on whole-cell extracts, cytosolic fractions, and mitochondrial fractions. The relative abundance of cytosolic mtDNA was assessed using the expression of the ND2 (F) and D-Loop (G) genes. Each symbol represents an individual donor. A Log2 fold change (FC) >0.5 or <-0.5 was considered significant, by Wilcoxon test.

Figure 5: Hydroxychloroquine restores the mitochondrial recycling in NK cells from SLE patients. (A) NK cells from HC (n=11) and SLE patients (n=11) were stimulated overnight with or without hydroxychloroquine (HCQ, 1 μM), followed by RT-qPCR analysis. The relative expression of mitophagy-related genes (LC3B, LAMP2, PINK1, PARK2, PIKC3C, GABARAPL2, ULK1, and BECL1) was assessed and normalized to HC samples. Each symbol represents an individual donor. A Log2 FC

>0.5 or <-0.5 was considered significant, by Kruskal-Wallis test. LC3B, light chain 3B; LAMP2, Lysosome-associated membrane protein 2; PINK1, PTEN Induced Kinase 1; PARK2, Parkinson disease 2; PIKC3C, class III phosphatidylinositol 3-kinase; GABARAPL1, GABA Type A Receptor Associated Protein Like 1; ULK1, Unc-51-like kinase 1; BECN1, Beclin 1

Supplemental figure 1: Specificity of mitochondrial mass increase within PBMCs from SLE patients and healthy controls. Mitochondrial mass (A-D) in NK (A), B- (B), CD8+ T- (C), CD4+T- (D) cells from HC (n=19) versus SLE patients (n=19), assessed at baseline by flow cytometry, using the MFI of MitoTracker Green. All readouts were performed at baseline, after overnight resting. Each symbol represents one individual. *p<0.05, by Wilcoxon test.

Supplemental figure 2: Impact of hydroxychloroquine concentration of NK cells phenotype alteration in healthy controls. Dot plots representing gating on NK cells (CD3-, CD56+) performed during the optimization of our assay measuring the lysosomal number, assessed by flow cytometry, using the MFI LysoTracker. PBMCs from healthy controls were stimulated overnight with ± bafilomycin (100nM), different concentrations of Hydroxychloroquine (HCQ): 0.01, 0.1, 1, 10, 100, 1000 µM or starved.

Figure 1: NK cells from SLE patients accumulate enlarged dysfunctional mitochondria.

Figure 2: NK cells from SLE patients fail to correctly acidify their lysosomes and maintain mitochondrial homeostasis.

Figure 3: NK cells from SLE patients harbor damaged mitochondria with disrupted ultrastructure and impaired mitophagy.

Figure 4: Hydroxychloroquine restores the cell function and mtDNA compartmentalization in NK cells from SLE patients.

A

Figure 5: Hydroxychloroquine restores the mitochondrial recycling in NK cells from SLE patients.